IL10 and cancer: However, as Zhuo et al. confirmed, the SNORA38B-driven overexpression of IL-10—verified using ELISA on culture supernatants—was observed in NSCLC cells, which further supports NSCLC IL-10 secretion as a pathogenic mechanism through which tumors evade the body’s innate, anti-cancer autoimmune responses (Figure 4a) [123].